Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
about
Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide.Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancyMicroglia/Astrocytes-Glioblastoma Crosstalk: Crucial Molecular Mechanisms and Microenvironmental Factors
P2860
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
@en
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
@nl
type
label
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
@en
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
@nl
prefLabel
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
@en
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
@nl
P2093
P2860
P921
P1433
P1476
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
@en
P2093
P2860
P2888
P356
10.1186/S12943-018-0759-3
P5008
P577
2018-01-12T00:00:00Z
P6179
1100381829